Fulcrum Therapeutics Gestione
Criteri Gestione verificati 2/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Alex Sapir
Amministratore delegato
US$3.3m
Compenso totale
| Percentuale dello stipendio del CEO | 19.99% |
| Mandato del CEO | 3yrs |
| Proprietà del CEO | 0.3% |
| Durata media del management | 3.3yrs |
| Durata media del Consiglio di amministrazione | 8.1yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Aggiornamento narrativa • Jul 10
FULC: Cash Review And Restructuring Will Drive Future Share Repricing
Fulcrum Therapeutics' analyst fair value estimate has been revised from $25.00 to about $16.75 as analysts factor in widespread rating downgrades and sharply reduced price targets, following the discontinuation of the pociredir program in sickle cell disease and the shift toward a cash-focused review of options. Analyst Commentary Recent research on Fulcrum Therapeutics points to a broad reset in expectations after the discontinuation of pociredir in sickle cell disease, with multiple firms revising ratings and price targets, and several explicitly framing the stock more as a cash-focused situation during the current review of options.
Aggiornamento narrativa • Jun 26
FULC: Cash-Rich Balance Sheet Will Shape Post-Program Review Outcome
The updated analyst price target for Fulcrum Therapeutics has shifted sharply lower, with the fair value estimate moving from about $19.00 to roughly $5.43. Analysts are factoring in the discontinuation of pociredir in sickle cell disease, class-wide safety concerns around PRC2 inhibitors, and the company's transition into a cash-focused story undergoing a review of alternatives.Seeking Alpha • Jun 03
Fulcrum: 'Hold' On Pociredir Discontinuation And Strategic Alternatives Shift
Summary Fulcrum Therapeutics maintains a 'Hold' rating after discontinuing pociredir for Sickle Cell Disease due to malignancy risk concerns tied to PRC2 inhibition. FULC's promising phase 1b SCD data showed robust HbF induction and favorable safety, but FDA feedback and class-wide malignancy signals halted development. With $333.3 million in cash, the company can fund operations into 2029, aided by cost reductions and a potential $100 million ATM facility. The company is exploring strategic alternatives, including mergers or asset acquisitions, but the timeline and outcome remain uncertain, justifying the continued 'Hold' stance. Read the full article on Seeking AlphaArticolo di analisi • Apr 01
Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. By way of example, Fulcrum...Nuova narrativa • Mar 20
Fetal Hemoglobin Induction Will Reshape Sickle Cell Care And Broaden Long Term Hematology Potential
Catalysts About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical stage biopharmaceutical company focused on small molecule treatments for genetically defined diseases, with an emphasis on sickle cell disease and hematologic conditions. What are the underlying business or industry changes driving this perspective?Nuova narrativa • Mar 04
Oral Fetal Hemoglobin Induction Will Reshape Severe Sickle Cell Treatment Over The Long Term
Catalysts About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical stage biopharmaceutical company focused on developing oral fetal hemoglobin inducers for sickle cell disease and other hemoglobinopathies. What are the underlying business or industry changes driving this perspective?Articolo di analisi • Sep 25
We're Not Very Worried About Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Fulcrum Therapeutics...Articolo di analisi • Apr 04
Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Business And Shares Still Trailing The Industry
You may think that with a price-to-sales (or "P/S") ratio of 1.7x Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) is a stock...Articolo di analisi • Dec 23
There's Reason For Concern Over Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Massive 34% Price Jump
Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) shareholders have had their patience rewarded with a 34% share price jump in...Articolo di analisi • Nov 08
We Think Fulcrum Therapeutics (NASDAQ:FULC) Can Easily Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Articolo di analisi • Sep 13
Some Confidence Is Lacking In Fulcrum Therapeutics, Inc. (NASDAQ:FULC) As Shares Slide 62%
Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) shareholders that were waiting for something to happen have been dealt a...Seeking Alpha • Sep 12
Fulcrum Therapeutics: Tough Day As Losmapimod FSHD Phase 3 Misses Badly
Summary Fulcrum Therapeutics, Inc.'s stock plummeted over 60% after its lead candidate, losmapimod, failed to meet primary and secondary endpoints in a Phase 3 study for FSHD. Despite prior optimism and significant investments from Sanofi and positive analyst ratings, the REACH trial's results were disappointing, leading to the suspension of the losmapimod program. Fulcrum's management, facing leadership changes and a challenging market, will now focus on its other clinical-stage candidate, pociredir, for sickle cell disease. With a market cap of $550m and nearly $300m in cash, the future value of Fulcrum's pipeline remains uncertain amidst intense competition. Read the full article on Seeking AlphaArticolo di analisi • Jul 12
Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?
Just because a business does not make any money, does not mean that the stock will go down. By way of example, Fulcrum...Articolo di analisi • Feb 11
Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Articolo di analisi • Oct 28
We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Articolo di analisi • Jul 11
We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Articolo di analisi • Nov 17
What You Need To Know About The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analyst Downgrade Today
The latest analyst coverage could presage a bad day for Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ), with the analysts...Articolo di analisi • Oct 18
We're Keeping An Eye On Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Articolo di analisi • Aug 13
Newsflash: Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analysts Have Been Trimming Their Revenue Forecasts
Today is shaping up negative for Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) shareholders, with the analysts delivering...Seeking Alpha • Aug 11
Fulcrum Therapeutics GAAP EPS of -$0.83 misses by $0.17, revenue of $1.9M misses by $1.06M
Fulcrum Therapeutics press release (NASDAQ:FULC): Q2 GAAP EPS of -$0.83 misses by $0.17. Revenue of $1.9M (-56.6% Y/Y) misses by $1.06M. As of June 30, 2022, cash, cash equivalents, and marketable securities were $169.0M, as compared to $218.2M as of December 31, 2021. Based on current operating plans, including successful implementation of the operational realignment, Fulcrum expects that its existing cash, cash equivalents, and marketable securities will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into mid-2024.Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$76m |
| Dec 31 2025 | US$3m | US$650k | -US$75m |
| Sep 30 2025 | n/a | n/a | -US$71m |
| Jun 30 2025 | n/a | n/a | -US$73m |
| Mar 31 2025 | n/a | n/a | -US$510k |
| Dec 31 2024 | US$1m | US$650k | -US$10m |
| Sep 30 2024 | n/a | n/a | -US$18m |
| Jun 30 2024 | n/a | n/a | -US$20m |
| Mar 31 2024 | n/a | n/a | -US$99m |
| Dec 31 2023 | US$7m | US$369k | -US$97m |
Compensazione vs Mercato: La retribuzione totale di Alex ($USD 3.25M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 1.62M ).
Compensazione vs guadagni: La retribuzione di Alex è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Alex Sapir (59 yo)
3yrs
Mandato
US$3,251,490
Compensazione
Mr. Alexander C. Sapir, also known as Alex, serves as Chief Executive Officer, President and Director at Fulcrum Therapeutics, Inc. since July 01, 2023. Mr. Sapir has been Director at PhaseBio Pharmaceutic...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, President & Director | 3yrs | US$3.25m | 0.30% $ 703.2k | |
| Chief Financial Officer | 2.9yrs | US$1.81m | 0% $ 0 | |
| Chief Legal Officer | 5.7yrs | US$1.48m | 0.015% $ 35.9k | |
| Founder | no data | Nessun dato | Nessun dato | |
| Founder | no data | Nessun dato | Nessun dato | |
| Founder | no data | Nessun dato | Nessun dato | |
| Founder | no data | Nessun dato | Nessun dato | |
| Founder | no data | Nessun dato | Nessun dato | |
| Chief Scientific Officer | 3.7yrs | Nessun dato | Nessun dato | |
| Chief People Officer | 5.7yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Early Development | 3.3yrs | Nessun dato | Nessun dato | |
| Head of Program Strategy & Vice President | 1.1yrs | Nessun dato | Nessun dato |
3.3yrs
Durata media
63yo
Età media
Gestione esperta: Il team dirigenziale di FULC è considerato esperto (durata media dell'incarico 3.3 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, President & Director | 3yrs | US$3.25m | 0.30% $ 703.2k | |
| Independent Director | 10yrs | US$274.91k | 0.14% $ 317.5k | |
| Independent Director | 1.7yrs | US$265.77k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 6.5yrs | US$279.41k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Director | 10yrs | US$269.41k | 0.68% $ 1.6m | |
| Independent Director | 9.6yrs | US$273.05k | 0.016% $ 38.2k | |
| Independent Chair of the Board | 8.1yrs | US$300.91k | 0% $ 0 | |
| Member of FSHD Clinical Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of FSHD Clinical Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of FSHD Clinical Advisory Board | no data | Nessun dato | Nessun dato |
8.1yrs
Durata media
68yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di FULC sono considerati esperti (durata media dell'incarico 8.1 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/13 09:42 |
| Prezzo dell'azione a fine giornata | 2026/07/13 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Fulcrum Therapeutics, Inc. è coperta da 16 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Dae Gon Ha | BTIG |
| Kristen Kluska | Cantor Fitzgerald & Co. |